HOUSE 19117th CongressReferred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Lower Costs, More Cures Act of 2021
- Last Action
- 10/19/2021
Actions
- 2021-10-19Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- 2021-04-22Referred to the Subcommittee on Health.
- 2021-04-21Referred to the Subcommittee on Health.
- 2021-04-21Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2021-04-21Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2021-04-21Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2021-04-21Introduced in House
- 2021-04-21Introduced in House
CRS Summary
As of 2021-04-21 (00)
Lower Costs, More Cures Act of 2021
This bill establishes and modifies several programs and requirements to address prescription drug prices.
The bill modifies provisions under Medicare and Medicaid relating to prescription drug coverage and price transparency. Among other changes, the bill
- requires the Centers for Medicare & Medicaid Services to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;
- caps annual out-of-pocket spending under the Medicare prescription drug benefit;
- allows prescription drug plan sponsors under the Medicare prescription drug benefit to offer additional plans in a region;
- requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and
- allows states to include in the Medicaid Drug Rebate Program covered outpatient drugs that are provided as part of physician or outpatient hospital services.
The bill also generally modifies other provisions relating to the regulation and costs of generic and brand-name drugs. Among other changes, the bill
- prohibits the manufacturer of a brand-name, generic, or biosimilar drug from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product;
- permanently allows high deductible health plans to waive deductibles for insulin and associated products; and
- establishes the position of Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative.
Cosponsors (20)
- KEVIN BRADY (R-TX)
- Virginia Foxx (R-NC)
- Brett Guthrie (R-KY)
- Devin Nunes (R-CA)
- Rick Allen (R-GA)
- Lloyd Smucker (R-PA)
- Dusty Johnson (R-SD)
- Richard Hudson (R-NC)
- David Schweikert (R-AZ)
- Andy Barr (R-KY)
- Ron Estes (R-KS)
- Earl Carter (R-GA)
- Robert Latta (R-OH)
- Gus Bilirakis (R-FL)
- Kevin McCarthy (R-CA)
- Jackie Walorski (R-IN)
- Greg Pence (R-IN)
- Tom Rice (R-SC)
- John Carter (R-TX)
- Troy Nehls (R-TX)
Subjects
- Accounting and auditing
- Administrative law and regulatory procedures
- Administrative remedies
- Appropriations
- Biological and life sciences
- Business records
- Chemistry
- Civil actions and liability
- Competition and antitrust
- Congressional oversight
- Consumer affairs
- Department of Health and Human Services
- Digestive and metabolic diseases
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Executive agency funding and structure
- Federal Trade Commission (FTC)
- Food and Drug Administration (FDA)
- Government information and archives
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.